Clinical trial
Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe…
NCT02937701 · Amgen, Industry · Completed
Key facts
| NCT number | NCT02937701 |
|---|---|
| Title | Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab |
| Official title | A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Biological |
| Interventions | ABP 710, Infliximab |
| Enrollment | 558 |
| Start date | Oct 10, 2016 |
| Primary completion | Apr 16, 2018 |
| Completion | Aug 13, 2018 |
| First posted | Oct 19, 2016 |
| Last update posted | Aug 28, 2019 |
| Countries | Australia, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: